Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company Deals

Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion

Fineline Cube Jun 29, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD...

Company Drug

AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants

Fineline Cube Jun 29, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...

Company Deals

Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share

Fineline Cube Jun 29, 2023

Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Shandong Buchang Pharmaceuticals’ BC001 Gets Clinical Trial Approval for Solid Tumors

Fineline Cube Jun 29, 2023

Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

Beijing Tiantan Biological Completes Phase I Study for Recombinant Coagulation Factor VIIa

Fineline Cube Jun 28, 2023

China-based Beijing Tiantan Biological Products Co., Ltd (SHA: 600161) has announced the conclusion of a...

Policy / Regulatory

Shanghai’s SMPA Notification: Non-Winning Bids in VBP Round 8 Can Avoid “Higher Price” Label

Fineline Cube Jun 28, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification concerning the 8th round of...

Company Legal / IP Policy / Regulatory

US FDA Issues Warning Letter to Chengdu KeCheng Fine Chemicals Over Communication Failures

Fineline Cube Jun 28, 2023

The US FDA’s Center for Drug Evaluation (CDE) issued a warning letter to China-based Chengdu...

Company Drug

Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging

Fineline Cube Jun 28, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Drug

Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China

Fineline Cube Jun 28, 2023

The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE:...

Company

Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health

Fineline Cube Jun 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...

Company Deals

Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics

Fineline Cube Jun 28, 2023

China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...

Company Drug

Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu

Fineline Cube Jun 28, 2023

South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has...

Company Drug

Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone

Fineline Cube Jun 28, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate,...

Company Deals

Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions

Fineline Cube Jun 27, 2023

Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar...

Policy / Regulatory

CDE Issues Guidelines for New Drug Benefit-Risk Assessment in Market Approval Filings

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has released a notice outlining the guidelines for “New...

Legal / IP Policy / Regulatory

CNIPA Launches Pilot for Priority Patent Review for Macau Applicants in Mainland China

Fineline Cube Jun 27, 2023

The China National Intellectual Property Administration (CNIPA) has announced the commencement of a pilot program...

Company Drug

AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes

Fineline Cube Jun 27, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received market approval...

Company Deals

Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction

Fineline Cube Jun 27, 2023

Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2...

Company Drug

LianBio’s Mavacamten Receives Priority Review Status from China’s CDE for oHCM Treatment

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that China-based biotech firm...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Posts pagination

1 … 455 456 457 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.